Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Department of Biochemistry and Molecular Biology, Virginia Commonwealth University Medical Center, Richmond, VA 23298-0614, USA; Department of Cell Biology, Microbiology and Molecular Biology, University of South Florida, Tampa, FL 33620, USA.
Prog Lipid Res. 2020 Apr;78:101031. doi: 10.1016/j.plipres.2020.101031. Epub 2020 Apr 24.
Glycolipid transfer proteins (GLTPs) were first identified over three decades ago as ~24kDa, soluble, amphitropic proteins that specifically accelerate the intermembrane transfer of glycolipids. Upon discovery that GLTPs use a unique, all-α-helical, two-layer 'sandwich' architecture (GLTP-fold) to bind glycosphingolipids (GSLs), a new protein superfamily was born. Structure/function studies have provided exquisite insights defining features responsible for lipid headgroup selectivity and hydrophobic 'pocket' adaptability for accommodating hydrocarbon chains of differing length and unsaturation. In humans, evolutionarily-modified GLTP-folds have been identified with altered sphingolipid specificity, e. g. ceramide-1-phosphate transfer protein (CPTP), phosphatidylinositol 4-phosphate adaptor protein-2 (FAPP2) which harbors a GLTP-domain and GLTPD2. Despite the wealth of structural data (>40 Protein Data Bank deposits), insights into the in vivo functional roles of GLTP superfamily members have emerged slowly. In this review, recent advances are presented and discussed implicating human GLTP superfamily members as important regulators of: i) pro-inflammatory eicosanoid production associated with Group-IV cytoplasmic phospholipase A; ii) autophagy and inflammasome assembly that drive surveillance cell release of interleukin-1β and interleukin-18 inflammatory cytokines; iii) cell cycle arrest and necroptosis induction in certain colon cancer cell lines. The effects exerted by GLTP superfamily members appear linked to their ability to regulate sphingolipid homeostasis by acting in either transporter and/or sensor capacities. These timely findings are opening new avenues for future cross-disciplinary, translational medical research involving GLTP-fold proteins in human health and disease. Such avenues include targeted regulation of specific GLTP superfamily members to alter sphingolipid levels as a therapeutic means for combating viral infection, neurodegenerative conditions and circumventing chemo-resistance during cancer treatment.
糖脂转移蛋白 (GLTPs) 三十多年前首次被发现,是一种约 24kDa 的可溶性两亲性蛋白,能够特异性加速糖脂的跨膜转移。发现 GLTPs 使用独特的全α-螺旋双层“三明治”结构 (GLTP 折叠) 结合糖鞘脂 (GSLs) 后,诞生了一个新的蛋白质超家族。结构/功能研究提供了精妙的见解,定义了负责脂质头部基团选择性和疏水性“口袋”适应性的特征,以适应不同长度和不饱和度的烃链。在人类中,已经鉴定出进化修饰的 GLTP 折叠具有改变的神经鞘脂特异性,例如神经酰胺-1-磷酸转移蛋白 (CPTP)、磷脂酰肌醇 4-磷酸接头蛋白-2 (FAPP2),其具有 GLTP 结构域和 GLTPD2。尽管有大量的结构数据 (>40 个蛋白质数据库存款),但 GLTP 超家族成员在体内的功能作用的见解进展缓慢。在这篇综述中,介绍和讨论了最近的进展,表明人类 GLTP 超家族成员是重要的调节剂:i) 与细胞质 IV 型磷脂酶 A 相关的促炎类二十烷酸的产生;ii) 自噬和炎症小体组装,驱动监控细胞释放白细胞介素-1β 和白细胞介素-18 炎症细胞因子;iii) 某些结肠癌细胞系的细胞周期停滞和坏死诱导。GLTP 超家族成员发挥的作用似乎与其通过作为转运体和/或传感器的能力来调节神经鞘脂稳态的能力有关。这些及时的发现为未来涉及人类健康和疾病的 GLTP 折叠蛋白的跨学科、转化医学研究开辟了新途径。这些途径包括通过靶向调节特定的 GLTP 超家族成员来改变神经鞘脂水平,作为治疗病毒感染、神经退行性疾病和规避癌症治疗中化疗耐药的一种手段。